Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bite

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    35 result(s) found for: Bite. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2005-004422-50 Sponsor Protocol Number: DM03RUP/IV/05 Start Date*: 2006-01-11
    Sponsor Name:J.Uriach y Compania S.A.,
    Full Title: A placebo-controlled, double-blind, cross-over study with rupatadine 10 mg in 30 mosquito-bite allergic adult subjects Rupatadiini-antihistamiini hyttyspistoallergiassa
    Medical condition: mosquito-bite allergic adults
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-004610-42 Sponsor Protocol Number: QA351 Start Date*: 2012-01-24
    Sponsor Name:London School of Hygiene and Tropical Medicine
    Full Title: Evaluation of topical ibuprofen and steroid in the reduction of local reactions and symptoms from an Aedes aegypti mosquito bite
    Medical condition: Inflamatory reaction to a mosquito bite
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004795-19 Sponsor Protocol Number: 120824001 Start Date*: 2013-03-12
    Sponsor Name:Folktandvården Västra Götaland
    Full Title: Utilisation of botulinum toxin type A on masticatory muscel hyperactivity in CP - a randomized, controlled study.
    Medical condition: Masticatory muscle hyperactivity/bruxism in patients with Cerebral Palsy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10028037 Movement disorders (incl parkinsonism) HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000117-39 Sponsor Protocol Number: A2301 Start Date*: 2011-06-14
    Sponsor Name:Ixodes AG.
    Full Title: A Phase 3 randomized, double-blind, placebo-controlled study of SHB004 (10% topical azithromycin) administered locally twice daily for three consecutive days for the prevention of Borreliosis in su...
    Medical condition: Lyme borreliosis
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004862 10067559 Lyme borreliosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-001599-18 Sponsor Protocol Number: BAY 12-8039/11974 Start Date*: 2006-11-03
    Sponsor Name:Bayer HealthCare AG
    Full Title: A prospective, randomized, double dummy, double blind, multinational, multicenter trial comparing the safety and efficacy of sequential (intravenous/oral) moxifloxacin 400 mg once daily to intraven...
    Medical condition: complicated skin and skin structure Infections
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040786 Skin structures and soft tissue infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) BE (Completed) LV (Completed) FR (Completed) GR (Completed) IE (Completed) HU (Completed) ES (Completed) NL (Prematurely Ended) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-005101-51 Sponsor Protocol Number: RIVM-V/330564/01 Start Date*: 2013-02-05
    Sponsor Name:National Institute of Health and the Environment (Dutch acronym: RIVM)
    Full Title: Tick Test & Prophylaxis Proof
    Medical condition: Lyme disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10025169 Lyme disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005184-29 Sponsor Protocol Number: P305-R-EG04 Start Date*: 2006-02-21
    Sponsor Name:GABA GmbH
    Full Title: Prevention of incipient carious lesions (white spot lesions) in patients with fixed orthodontic appliances following the application of elmex® gelée
    Medical condition: incipient carious lesions (white spot lesions)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001491-36 Sponsor Protocol Number: Bay 12-8039/12670 Start Date*: 2008-09-25
    Sponsor Name:BAYER
    Full Title: ''A prospective, randomized, open label, active comparator, multicenter, national trial to compare the efficacy and safety of sequential IV/PO moxifloxacin 400 mg once daily versus IV amoxicillin/c...
    Medical condition: cSSSIs
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040872 Skin infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002476-92 Sponsor Protocol Number: 20120215 Start Date*: 2015-06-29
    Sponsor Name:Amgen Inc
    Full Title: A Randomized, Open-label, Controlled Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab as Consolidation Therapy Versus Conventional Consolidatio...
    Medical condition: Patients with Philadelphia chromosome negative (Ph-) high-risk (HR) first relapse B-precursor ALL (as defined by I-BFM SG/IntReALL criteria)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    21.1 100000004864 10066109 Precursor B-lymphoblastic leukemia acute LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BE (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PL (Completed) ES (Ongoing) FR (Completed) NL (Completed) Outside EU/EEA GR (Completed) NO (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2011-005477-24 Sponsor Protocol Number: VAC045 Start Date*: 2012-02-28
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-boost Malaria Vaccine Candidates: ChAd63 and MVA encoding ME-TRAP and the same Viral Vectors encoding CS
    Medical condition: Plasmodium falciparum infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004674-94 Sponsor Protocol Number: WI237607 Start Date*: 2019-04-05
    Sponsor Name:Riga Stradiņš University
    Full Title: Open-label Phase IV Study to Investigate Broad-and Cross-neutralizing Antibodies after Primary Vaccination with Two Different TBE Vaccines
    Medical condition: Active (prophylactic) immunization against tick-borne encephalitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10043847 Tick-borne viral encephalitis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004674-17 Sponsor Protocol Number: NL59901.078.17 Start Date*: 2017-10-17
    Sponsor Name:Princess Máxima Center for Pediatric Oncology
    Full Title: A pilot study to test the feasibility, safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia...
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) AT (Completed) BE (Completed) DK (Completed) DE (Completed) CZ (Completed) FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-000536-10 Sponsor Protocol Number: 00103311 Start Date*: 2013-11-13
    Sponsor Name:Amgen Inc.
    Full Title: A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE® Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acu...
    Medical condition: Adult patients with relapsed and/or refractory B-precursor Acute lymphoblastic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    14.1 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) DE (Completed) BE (Completed) IE (Completed) AT (Completed) GB (Completed) ES (Completed) FR (Completed) GR (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-002879-17 Sponsor Protocol Number: 20160370 Start Date*: 2019-06-18
    Sponsor Name:Amgen Inc
    Full Title: A Phase 1b/2 Multicenter, Open-label, Expansion Study to Assess the Safety and Efficacy of AMG 420 as Monotherapy in Subjects With Relapsed and/or Refractory Multiple Myeloma
    Medical condition: Relapsed or Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018314-75 Sponsor Protocol Number: MT103-203 Start Date*: 2010-08-05
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor...
    Medical condition: minimal residual disease (MRD) of B-precursor ALL
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001049-28 Sponsor Protocol Number: VAC067 Start Date*: 2017-05-26
    Sponsor Name:University of Oxford, CTRG
    Full Title: A Phase I/II Study to assess the safety, immunogenicity and protective efficacy of novel malaria vaccine candidates ChAdOx1 LS2 and MVA LS2 in healthy UK adults
    Medical condition: Plasmodium falciparum infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-023747-15 Sponsor Protocol Number: 070411 Start Date*: 2011-05-03
    Sponsor Name:University of Oslo
    Full Title: Tick borne diseases in norwegian general practice. A randomized, controlled trial for treatment of erythema migrans in norwegian general practice. A comparison of phneoxymetylpenicillin, amoxicilli...
    Medical condition: Erythema migrans (Early Lyme disease)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10015157 Erythema chronicum migrans LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: View results
    EudraCT Number: 2009-015989-62 Sponsor Protocol Number: MT103-206 Start Date*: 2010-08-05
    Sponsor Name:Amgen Research (Munich) GmbH
    Full Title: An Open Label, Multicenter, Exploratory Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of the BiTE Antibody Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Ac...
    Medical condition: Patients with Relapsed/Refractory B-Precursor acute lymphoblastic leukemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004416-66 Sponsor Protocol Number: VAC052 Start Date*: 2012-11-26
    Sponsor Name:University of Oxford
    Full Title: A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches using the ChAd63 and MVA vectors encoding the antigens ME-TRAP, CS and AMA1.
    Medical condition: Plasmodium falciparum Infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-001265-92 Sponsor Protocol Number: VAC065 Start Date*: 2016-06-24
    Sponsor Name:University of Oxford, CTRG
    Full Title: A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of adjuvanted R21 at different doses and the Combination Malaria Vaccine Candidate Regimen of adjuvanted R21 + ...
    Medical condition: Plasmodium falciparum infection
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 08:20:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA